RT Journal Article
SR Electronic
T1 Genomic epidemiology of SARS-CoV-2 in Russia reveals recurring cross-border transmission throughout 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.31.21254115
DO 10.1101/2021.03.31.21254115
A1 Matsvay, Alina
A1 Klink, Galya V.
A1 Safina, Ksenia R.
A1 Nabieva, Elena
A1 Garushyants, Sofya K.
A1 Biba, Dmitry
A1 Bazykin, Georgii A
A1 Mikhaylov, Ivan M.
A1 Say, Anna V.
A1 Zakamornaya, Anastasiya I.
A1 Khakhina, Anastasiya O.
A1 Lisitsa, Tatiana S.
A1 Ayginin, Andrey A.
A1 Abramov, Ivan S.
A1 A.Bogdan, Sergey
A1 Kolbutova, Kseniya B.
A1 Oleynikova, Daria U
A1 Avdeenko, Tatiana F.
A1 Shipulin, German A.
A1 M.Yudin, Sergey
A1 Skvortsova, Veronika I.
YR 2021
UL http://medrxiv.org/content/early/2021/04/16/2021.03.31.21254115.abstract
AB SARS-CoV-2 has spread rapidly across the globe, with most nations failing to prevent or substantially delay its introduction. While many countries have imposed some limitations on trans-border passenger traffic, the effect of these measures on the spread of COVID-19 strains remains unclear. Here, we report an analysis of whole-genome sequencing of 3206 SARS-CoV-2 samples from 78 regions of Russia covering the period between March and November 2020. We describe recurring imports of multiple COVID-19 strains throughout this period, giving rise to 457 uniquely Russian transmission lineages, as well as repeated cross-border transmissions of local circulating variants out of Russia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by the RFBR, project number 20-04-60556 to G.A.B.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was presented to the Local Ethics Committee at the Centre of Hygiene and Epidemiology. The Committee concluded (protocol #03-04/20 of March 2, 2020) that the study does not make use of identifiable biological samples and does not bring forward any new sensitive data, since all samples were deidentifed prior to receipt by the study team. Therefore, according to the rules of the Committee and national regulations, this project does not require ethical approval. Written informed consent was obtained from all study participants. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll primary sequencing data obtained in this study together with corresponding metadata is being deposited to GISAID.